Governor Robert McDonnell of Virginia visited the Focused Ultrasound Center at the University of Virginia yesterday. Dedicated in September 2009, the center is the first to receive the Focused Ultrasound Surgery Foundation’s “Center of Excellence” designation and is a hub for performing multidisciplinary preclinical and clinical research, training and patient treatments at the highest level.
Profound Medical Inc. (PMI) and Siemens Healthcare have announced plans to conduct a global, multi-site, human safety/feasibility clinical trial initiative involving early stage prostate cancer patients in Europe, the U.S. and Canada.
In making the announcement, PMI's CEO Paul Chipperton observed, "We are developing a truly unique, minimally-invasive medical device for the treatment of prostate cancer, combining the already proven clinical efficacy of ultrasound thermal therapy with the unparalleled imaging capabilities of MRI." He had previously said that the new device has the potential to treat patients three to six times faster than existing options with greater accuracy and fewer side effects.
Tina Krall, executive director of Fibroid Relief, the FUS Foundation's inaugural patient support organization, was a guest today on "Real Women on Health," a radio program hosted by Kelley Connors. Real Women on Health is an online community and radio show for women who want to be their own health and wellness advocates. Joining Krall on the program were John Fischer, M.D. of St. Luke’s Episcopal Hospital in Houston and Wendy Perkins, a patient advocate who opted to treat her uterine fibroids with MR-guided focused ultrasound. Krall and Fischer will also appear at the Fibroid Relief at Last Event scheduled for April 27 in Houston.
According to Krall, today's program featured a discussion of various treatment options for uterine fibroids and provided "a lot of great coverage for focused ultrasound." Here is a link to a recording of the show: http://blogtalk.vo.llnwd.net/o23/show/1/771/show_1771371.mp3
During last month's meeting of the European Congress of Radiology in Vienna, Philips Healthcare announced that its Sonalleve MR-HIFU system has received CE Marking for palliative care of patients with bone metastases. Equivalent to FDA approval in the U.S., CE Marking is recognized by countries in the European Economic Area and signifies that a product complies with the essential requirements of relevant health, safety and environmental protection legislation.
The company acknowledged that it intends to seek similar approval in the U.S.
Philips has been marketing the Sonalleve for uterine fibroid treatment since December 2009 and has installed 22 systems worldwide. The Sonalleve system uses ultrasound energy to ablate metastatic tissue and sensitive nerves around the bone, alleviating the significant pain experienced by advanced cancer patients. The system's MR imaging provides 3D planning and temperature monitoring.